MedTrace Logo

Analyzing and Solving Exceptional Long-term Survivors in Solid Tumors With Poor Prognosis

NCT06160596 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 1020

Last updated 2023-12-07

No results posted yet for this study

Summary

This is a retrospective, exploratory, multi-center, translational, 3 cohorts case control matched study conducted in patients harboring a solid tumor with poor prognosis who presented a long-term (case) and standard (standard) survival.

Patients with:

* Cohort A: metastatic pancreatic ductal adenocarcinoma
* Cohort B: glioblastoma IDHwt
* Cohort C: extensive small cell lung cancer

This research aims to integrate data generated from clinical records, imaging, multi-omics and bioinformatics approaches to discriminate case and control and then to identify new therapeutic targets. Analyses will be performed depending on the tumor samples available with at least 3 omics levels and according to scientific advances; genomic, epigenomic, proteomics, metabolomics, transcriptomic, microbiomic.

Conditions

  • Pancreas Adenocarcinoma
  • Small-cell Lung Cancer
  • Glioblastoma, IDH-wildtype

Interventions

GENETIC

Long term survival multimodal analysis

* To describe global signatures (Digital histology, Radiomic, Genomic, Transcriptomic, Proteomic, (Epigenomic) and clinical signature) that are associated with a patient's unexpected survival compared to standard patients across three cohorts of solid tumors with unmet medical needs. * To describe global signatures in the overall population (pan-cohort). * To describe clinical, digital pathology, radiomic, genomic, transcriptomic, proteomic and epigenomic signatures associated with patients' unexpected survival compared to standard patients for each cohort and in all cohorts (pan-cohort)

Sponsors & Collaborators

  • Gustave Roussy, Cancer Campus, Grand Paris

    collaborator OTHER

  • Centre Leon Berard

    collaborator OTHER

  • Vall d'Hebron Institute of Oncology

    collaborator OTHER

  • Istituto Europeo di Oncologia

    collaborator OTHER

  • Charite University, Berlin, Germany

    collaborator OTHER

  • Cure 51

    lead OTHER

Principal Investigators

  • Julieta Rodriguez, MD · Gustave Roussy, Cancer Campus, Grand Paris

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-11-01
Primary Completion
2025-11-01
Completion
2028-05-01

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06160596 on ClinicalTrials.gov